Thursday, September 07, 2023
Clearmind Medicine has entered into a clinical trial agreement with Johns Hopkins University School of Medicine to conduct its Phase I/IIa clinical trial of its proprietary MEAI-based CMND-100, known as CM-CMND-001.
This clinical trial is designed as a multinational, multi-centre study and aims to assess the tolerability, safety, and pharmacokinetics of CMND-100 in both healthy volunteers and individuals with alcohol use disorder (AUD).
This clinical trial represents an important step in exploring the potential of psychedelic drugs like CMND-100 to address neuropsychiatric conditions such as AUD and contribute valuable insights into their therapeutic use.
The primary objective of the CM-CMND-001 clinical trial is to determine the tolerable dosage of CMND-100 and to characterise its safety and pharmacokinetics/pharmacodynamics (PK/PD) in subjects receiving single and repeated doses.
Additionally, the secondary objective of the trial is to assess the effectiveness of CMND-100 in reducing drinking patterns and cravings among individuals with moderate-to-severe AUD. To achieve this, oral capsules of CMND-100 will be administered once daily for ten consecutive days. During the course of the clinical trial, patients will report their drinking patterns and cravings for alcohol, as well as their cravings for cigarettes if applicable.
